Trials / Unknown
UnknownNCT02389920
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Describe the purpose of the study: This study aims to evaluate the improvement of Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-02-01
- Completion
- 2018-12-01
- First posted
- 2015-03-17
- Last updated
- 2015-03-17
Source: ClinicalTrials.gov record NCT02389920. Inclusion in this directory is not an endorsement.